Notably, increased levels of MSUT2 could be demonstrated in different tauopathies and at different disease stages, as patients with mild cognitive impairment (MCI), AD, and CBD all showed significantly greater levels of MSUT2 (Fig. 1h–k). This evidence concerns the gene ZC3H14 and Alzheimer disease.